BST:HQP

Stock Analysis Report

Executive Summary

PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, Asia, Europe, Australia, Africa, and New Zealand.


Snowflake Analysis

Good value with reasonable growth potential.


Similar Companies

Share Price & News

How has Kimia Farma (Persero)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HQP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-23.2%

HQP

-7.2%

DE Pharmaceuticals

-6.8%

DE Market


1 Year Return

-83.5%

HQP

10.8%

DE Pharmaceuticals

6.5%

DE Market

Return vs Industry: HQP underperformed the German Pharmaceuticals industry which returned 11.8% over the past year.

Return vs Market: HQP underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

HQPIndustryMarket
7 Day-23.2%-7.2%-6.8%
30 Day-40.6%-3.2%-3.7%
90 Day-66.3%4.4%-3.6%
1 Year-83.4%-83.5%14.7%10.8%9.8%6.5%
3 Year-72.3%-72.8%32.2%17.3%6.8%-2.6%
5 Year-63.0%-64.2%31.0%9.4%12.5%-2.9%

Price Volatility Vs. Market

How volatile is Kimia Farma (Persero)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kimia Farma (Persero) undervalued compared to its fair value and its price relative to the market?

16.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: HQP (€0.03) is trading above our estimate of fair value (€0.01)

Significantly Below Fair Value: HQP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HQP is good value based on its PE Ratio (17.9x) compared to the Pharmaceuticals industry average (24.1x).

PE vs Market: HQP is good value based on its PE Ratio (17.9x) compared to the German market (20.2x).


Price to Earnings Growth Ratio

PEG Ratio: HQP is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: HQP is good value based on its PB Ratio (0.6x) compared to the DE Pharmaceuticals industry average (2.1x).


Next Steps

Future Growth

How is Kimia Farma (Persero) forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

32.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HQP's forecast earnings growth (32.3% per year) is above the savings rate (-0.4%).

Earnings vs Market: HQP's earnings (32.3% per year) are forecast to grow faster than the German market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HQP's revenue (19.5% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: HQP's revenue (19.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HQP's Return on Equity is forecast to be low in 3 years time (15%).


Next Steps

Past Performance

How has Kimia Farma (Persero) performed over the past 5 years?

7.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HQP has a large one-off gain of IDR38.9B impacting its September 30 2019 financial results.

Growing Profit Margin: HQP's current net profit margins (2.8%) are lower than last year (4.6%).


Past Earnings Growth Analysis

Earnings Trend: HQP's earnings have grown by 7.2% per year over the past 5 years.

Accelerating Growth: HQP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HQP had negative earnings growth (-35.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.4%).


Return on Equity

High ROE: HQP's Return on Equity (1.8%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Kimia Farma (Persero)'s financial position?


Financial Position Analysis

Short Term Liabilities: HQP's short term assets (IDR7,149.9B) exceed its short term liabilities (IDR6,316.2B).

Long Term Liabilities: HQP's short term assets (IDR7,149.9B) exceed its long term liabilities (IDR3,639.6B).


Debt to Equity History and Analysis

Debt Level: HQP's debt to equity ratio (96.5%) is considered high.

Reducing Debt: HQP's debt to equity ratio has increased from 18.1% to 96.5% over the past 5 years.

Debt Coverage: HQP's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: HQP's interest payments on its debt are not well covered by EBIT (1.4x coverage).


Balance Sheet

Inventory Level: HQP has a high level of physical assets or inventory.

Debt Coverage by Assets: HQP's debt is not covered by short term assets (assets are 0.9x debt).


Next Steps

Dividend

What is Kimia Farma (Persero)'s current dividend yield, its reliability and sustainability?

2.63%

Forecast Dividend Yield


Dividend Yield vs Market

company0%marketbottom25%1.5%markettop25%3.8%industryaverage3.0%forecastin3Years2.6%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate HQP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HQP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HQP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HQP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: HQP is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HQP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Kimia Farma (Persero) has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
- Pardiman
Financial Director & Director0.4yrsno datano data
Fonny Yulina
Head of Compliance & Risk Management Unit5.5yrsno datano data
Dharma Syahputra
General Affair & Human Capital Director and Director1.1yrsno data0.00032% IDR818.3
R. Ikhwani
Head of Internal Control Unit4.8yrsno datano data
Verdi Budidarmo
Director of Production & Supply Chain and Director2.8yrsno datano data
Andi Prazos
Business Development Director & Director1.1yrsno datano data
Imam Fathorrahman
Business Development Director & Director0.4yrsno datano data
Ganti Putro
General Manager of Corporate Secretary2.3yrsno datano data

1.7yrs

Average Tenure

50yo

Average Age

Experienced Management: HQP's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
- Pardiman
Financial Director & Director0.4yrsno datano data
Dharma Syahputra
General Affair & Human Capital Director and Director1.1yrsno data0.00032% IDR818.3
Verdi Budidarmo
Director of Production & Supply Chain and Director2.8yrsno datano data
Andi Prazos
Business Development Director & Director1.1yrsno datano data
Imam Fathorrahman
Business Development Director & Director0.4yrsno datano data
Wahono Sumaryono
Independent Commissioner9.1yrsno datano data
Untung Sutarjo
President Commissioner1.8yrsno datano data
Muhammad Fauzi
Commissioner3.8yrsno datano data
Chrisma Albandjar
Commissioner1.8yrsno datano data
- Nurrachman
Independent Commissioner1.8yrsno datano data

1.8yrs

Average Tenure

50yo

Average Age

Experienced Board: HQP's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Kimia Farma (Persero) Tbk's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Kimia Farma (Persero) Tbk
  • Ticker: HQP
  • Exchange: BST
  • Founded: 1817
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp3.888t
  • Listing Market Cap: Rp255.728m
  • Shares outstanding: 5.55b
  • Website: https://kimiafarma.co.id

Number of Employees


Location

  • PT Kimia Farma (Persero) Tbk
  • Kantor Pusat
  • Jalan Veteran No. 9
  • Jakarta
  • 10110
  • Indonesia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KAEFIDX (Indonesia Stock Exchange)YesSeries B SharesIDIDRJul 2001
HQPBST (Boerse-Stuttgart)YesSeries B SharesDEEURJul 2001

Biography

PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, Asia, Europe, Australia, Africa, and New Zealand. It operates through Production, Distribution, Retail, and Others segments. It also provides hormones, narcotics, raw materials, contraceptives, OTC products, cosmetic and body care products, and food supplements. In addition, the company distributes medicines; and operates drug materials plants. It sells its products to pharmacies, hospitals, drugstores, and modern markets. As of December 31, 2018, the company had 1,190 outlets, including 283 jointly operated pharmacy outlets; and 905 owned pharmacy outlets, as well as 2 franchises in Indonesia. It operates 530 health clinics. The company was founded in 1817 and is headquartered in Jakarta, Indonesia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 22:09
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.